Oseltamivir is contraindicated for people aged 10-19 in principle in Japan, due to concern about abnormal behaviours. Sudden death is another concern. This review examines growing evidence of their association and discusses underlying mechanisms of these sudden-onset type reactions to oseltamivir. First, the importance of animal models and the concept of human equivalent dose (HED) is summarized. Second, the specific condition for oseltamivir use, influenza infection, is reviewed. Third, findings from toxicity studies conducted prior to and after the marketing of oseltamivir are reported on to provide context on the observation of a possible causal association.
However, serious neuropsychiatric adverse reactions to oseltamivir, including sudden death and abnormal behaviours leading to accidental death, were reported soon after the drug was introduced as a medicine. [5] [6] [7] Prospective cohort studies [16] [17] [18] [19] [20] and a systematic review of the prospective cohort studies 21 indicate an association between abnormal behaviours and oseltamivir use. A recent systematic review and meta-analysis of both treatment and prophylaxis randomized controlled trials including adults and children shows that oseltamivir increased risk of nausea; vomiting; headaches; psychiatric, renal, diabetic/hyperglycaemic events; and pain in the limbs. However, zanamivir did not. 22 According to the prospective cohort studies, [16] [17] [18] [19] [20] [21] NNTH (number needed to treat to harm) of oseltamivir for abnormal behaviours is estimated about 25 (95% CI: [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Oseltamivir was prescribed to 2.85 million people during the 2013/2014 winter season in Japan. 23 If oseltamivir causes abnormal behaviours, more than 100 thousand persons could experience additional oseltamivir-associated abnormal behaviours. While sudden deaths or very early deteriorations leading to death were specifically reported after taking oseltamivir, none have been reported for zanamivir. 24 Among 10 million people who were prescribed with oseltamivir during 2009/2010 season in Japan, 38 patients deteriorated within 12 hours after taking oseltamivir before death. 24 On the other hand, among 61 sudden death cases that were reported to FDA and health Canada including reports from Japan This review describes growing evidence from non-clinical studies that contradicts the widely held opinion that there is no association between oseltamivir use and abnormal behaviour or sudden death.
We first comment on the important role that animal models play in predicting human toxicities and the concept of human equivalent dose (HED) is summarized, for better understanding of evidence from animal toxicity studies. Second, the specific condition under which oseltamivir is used to treat patients infected with influenza is described. Third, findings from toxicity studies conducted prior to and after the marketing of oseltamivir are reviewed to consider the strength and consistency of causal association. Fourth, similarity and consistency of toxicity findings in humans with that in other animals is reported. Finally, coherence of toxicokinetic and molecular level of evidence (channels, receptors and enzymes), including differences from the toxicity of other neuraminidase inhibitors, is reviewed.
| PRINCIPLES OF ANIMAL TOXICITY TESTS

| Objective: to predict toxicity in humans
Zbinden, a researcher at Roche Pharmaceutical, writes as follows about the objectives of the animal toxicity tests. 
It would be very desirable if the harmful effects of new-
| Human equivalent dose
To accurately understand animal toxicity data, the conversion factor for converting animal dose to human equivalent dose (HED), described in the "Guidance for Industry" for a person weigh- 
| Summary of this section
We discussed the importance of animal models mimicking clinical use and bold exaggerations with respect to clinical dose for predicting human toxicities and the importance of human equivalent dose (HED) concept for better understanding of evidence from animal toxicity studies. 34 The pharmacokinetic (PK) parameters are not so different in healthy children aged 3 years or older from what they are in adults. 35 Almost all OC is secreted in urine and dose adjustment is necessary if a patient's creatinine clearance is <30 mL/min.
34,37,39
Suzaki et al. 40 reported one subject who showed an approximately ten-fold higher peak concentration (Cmax) and area under the con- adult Thai volunteers showed an AUC six times greater than the average of the other subjects. 41 These differences are derived from difference in the activity of carboxylesterase which metabolizes OT to OC.
40,41
One of the peculiar pharmacokinetic characters of oseltamivir is the bimodal peak of plasma OT concentration. 40 This is probably related to the bimodal abnormal behaviours with dyspnoea in a 14-year-old boy (case 6), 6 and deaths during 8-24 hours after one dose of oseltamivir in rat toxicity test may also be related as discussed in the section 4 (or section for toxicity and toxicokinetic studies).
| Action and pharmacokinetics of oseltamivir in infected patients or animal models
| Influenza and pro-inflammatory cytokines
Oseltamivir is taken primarily for treatment of influenza. In influenzainfected individuals, as with other infections, pro-inflammatory cytokines such as interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) are induced. 
| Infectious state and carboxylesterase
Treatment with IL-6 in vitro decreased the expression of human hCE1
and hCE2 by as much as 60%. The decreased expression occurred at both mRNA and protein levels and was confirmed by enzymatic assay.
43
Pharmacokinetic parameters of oseltamivir in plasma during influenza infection were not provided. However, it can be assumed that the activity of hCE is reduced during the early phase or exacerbated state of influenza infection and that subsequently, concentration of unchanged OT may increase in plasma.
| Infectious state and P-glycoprotein (P-gp)
P-glycoprotein is a critical efflux transporter at the blood-brain barrier (BBB) where its luminal location and substrate promiscuity limit the brain distribution of numerous therapeutics. P-gp is highly regulated by inflammatory mediators.
44
Inflammation and infection produce dynamic changes in P-gp expression and activity in the blood-brain barrier. In vitro, BBB P-gp activity is downregulated after short-term exposure to inflammatory mediators, 45, 46 while its activity is upregulated following more prolonged exposure, 47 or in experimental model of chronic, peripheral inflammatory pain in rats.
43,46
Pharmacokinetic parameters during influenza infection were not provided in the brain either. However, it can be assumed that the activity of P-gp is reduced during the early phase or exacerbated state of influenza infection and that subsequently, brain concentration of unchanged OT may increase.
| Hepatic carboxylesterase (hCE) and P-gp in immaturity
The esterase (hCE) activity is low in infants less than one year old and in immature animals. 35, 48 P-gp expression in the mouse brain increases with maturation. 49 Hence, it can be assumed that plasma and brain concentrations of unchanged OT may increase in immature animals, including humans.
| Animal models of influenza infection
Animal toxicity (Tx) tests and toxicokinetic (TK) tests on juvenile rats before weaning (usually 7-day-old pups, weighing about 11-23 g), on mature rats using intraduodenal injection by catheter and intravenous administration which produces high plasma level and brain level of oseltamivir, provide good animal models for detecting toxicities in human influenza in the absence of pharmacokinetic data on influenza infection in humans.
34-38,50-52
In fact, the brain-to-plasma concentration ratio of oseltamivir is significantly higher in newborn rats than in mature rats, which is consistent with the ontogenetic expression profile of P-gp.
49
| 151
| Spontaneous recovery of hCE and P-gp in the course of influenza
During the acute phase of influenza, pro-inflammatory cytokines increase; the plasma oseltamivir level may increase due to decreased hCE activity; and the brain/plasma ratio of oseltamivir level may increase due to downregulated BBB P-gp activity. It can be speculated that during the convalescent period, the activity of hCE and BBB P-gp may recover as pro-inflammatory cytokine level decreases.
In the same way, activity of hCE and BBB P-gp may increase with growth.
| Brain/plasma concentration of oseltamivir in pregnant mothers and newborns
Patterns of expression of cytokines in the foetal membranes and decidua suggest that inflammatory activation occurs modestly with term labour, but much more robustly in preterm delivery, particularly in the presence of intrauterine infection.
53
Therefore, the brain-toplasma ratio of Cmax undoubtedly increases more in cases of abortion and preterm delivery than during term labour, particularly in the presence of intrauterine infection.
Maternal plasma oseltamivir may readily pass the placenta, and plasma concentration in foetus may be half that of the maternal plasma concentration. 34, 35 Carboxylesterase 48 and brain P-gp 49 of newborns are particularly immature, and newborn infants are at very high risk of brain exposure of oseltamivir. The topic of adverse effects on pregnant mothers, foetuses and newborns will be discussed elsewhere, as space in this review is limited.
| Summary of this section
Cmax and AUC of oseltamivir in non-infectious state vary greatly, and bimodal peak concentration is sometimes observed. In influenza infection to which oseltamivir is used and in immaturity, plasma and brain concentrations of OT increase due to inhibition of carboxylesterase in the liver and P-gp in the BBB, respectively. Hence, newborn animals are the good models for predicting and confirming the toxicity of oseltamivir.
| TOXICITY AND TOXICOKINETIC STUDIES IN JUVENILE RATS: AN EXCELLENT ANIMAL MODEL OF HUMAN INFLUENZA INFECTION
As we do not have pharmacokinetic (PK) parameters for the human infectious state of influenza, toxicity studies (Tx studies) and toxicokinetic (TK) parameters from juvenile rats, a good animal model of infection, provide the navigation chart for estimating what toxicity effects might appear in humans.
| Mortality from toxicity studies before and after approval of oseltamivir
The drug's manufacturer conducted a series of acute Tx studies using 7-day-old rats (before weaning). At least seven such tests are known:
(i) a dose-finding preliminary Tx study (dose-finding Tx); (ii) a Tx study, along with (iii) a TK study performed before approval of oseltamivir for 32 Figure 1 shows the relationship between dose and probability of death using the data from all toxicity and TK studies. The numbers of rat pups that died and the denominators of each study are shown in Table 1 . In the TK studies (e.g. in the post-marketing TK study), each group started with 96 pups, and six pups (three of each sex) were sacrificed at 0.25, 0.5, 1, 1.5, 2, 4 and 8 hours for determination of blood and brain concentration before the end of the study (24 hours).
Hence, the observed total rat-days were estimated at 58.3 (In the case It is noted that among 40 pups died within 24 hours after a single dose oseltamivir, 15 died within 4 hours and 25 died after 8 hours postdosing. 51 This may be related to the bimodal peak concentration of OT.
40
F I G U R E 1 Dose of oseltamivir and mortality trend in 7-day-old rats. Data from Refs. (35, 36, (50) (51) (52) . In the TK tests, the proportion of deaths is underestimated because rats were withdrawn for determination of plasma and brain concentration (see the footnote of Table 1 ). The results show that for each additional dose of 100 mg/ kg, the odds of death more than double (OR=2.26, 95% CI: 2.01-
2.54, P<.0001)
T A B L E 1 Mortality of 7-day-old rats from toxicity tests (Tx) and toxicokinetic (TK) tests For the TK tests, denominators were expressed as rat-days (Rds), calculated using the number of rats sacrificed for determination of plasma and brain concentrations at each time point. For example, in study 7 (Post-M TK), six rats each were withdrawn at 0.25, 0.5, 1, 1.5, 2, 4 and 8 hours before the end of observation and the last measurement. Chi-square value for linear trend=432.1, P<.0001. Dose of oseltamivir and proportion of death in 7-day-old rats using the number of rats at the start of the studies as denominators are shown in Fig. 1 .
a Pre-1:before approval of oseltamivir for children, b Pre-2: before approval of oseltamivir capsule for prophylaxis.
c Post-M: post-marketing toxicity study. Tx: toxicity study. TK: toxicokinetic study.
d
High mortality may be due to the rats having lower body weight. Although their weights were not shown, the rats used in the Pre-1 Tx and TK studies weighed less (11.5-18.9 g) than those in studies 4 and 5 (14.0-26.0), which means they were less grown. Body weight of the rats in post-marketing Tx and post-marketing TK studies were not shown.
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In a juvenile rat toxicity study, a single dose of 114 mg/kg oseltamivir (expressed as free base; the same applies below unless otherwise explained) was the "no observable adverse effect level" (NOAEL) for death (also called NODEL: no observable death effect level). As the PK parameters for influenza-infected humans are not available, the human equivalent dose (HED) was calculated using the following formula: 
| Suppression of central nervous system known before marketing
Respiratory suppression is one of the most serious reactions to suppressants of the central nervous system, including barbiturates and benzodiazepines, because respiratory suppression is followed by cardiac arrest and sudden death. 54 Suppression of the central nervous system, including respiratory suppression, hypoactivity or sleep (low arousal) followed by sudden death, was observed in at least seven of eight animal toxicity studies of oseltamivir. At least five of these studies were conducted and submitted to the regulators for approval, [34] [35] [36] and at least two were conducted after approval by the pharmaceutical industry for confirmation of the causality.
50,52
Signs of central nervous system disorders, such as abnormal gait with shallow respiration and seizure, were observed in a surviving mouse administered a single intravenous dose of 190 mg/kg (HED=20 mg/kg). 34 The "no observable adverse effects level" (NOAEL)
of OT was 38 mg/kg (HED=4.1 mg/kg).
In a one-week oral toxicity study, all four marmoset monkeys treated with 1522 mg/kg of oseltamivir as free base were sacrificed due to impending death within 4 days (one on day 2, the others on day 4), with manifestations of hypoactivity, sleep and collapse before sacrifice. The NOAEL of OT in this study was 76 mg/kg (HED=12 mg/kg).
34
In a dose-finding toxicity study on 7-day-old rats (juvenile rats weighing 11.5-18.9 g), 18 of 24 treated with doses of 761 mg/kg (HED=78 mg/kg) died within seven hours after treatment. Lung oedema was observed in nine of the 18 dead rats on histological examination. Lung oedema is very often observed in cases of sudden death during sleep in both infants and adults. 6 No deaths were observed in 114 mg/kg (HED=12.2 mg/kg) or lower dose groups, including the vehicle group 35 (Table 1) .
In the Tx studies on 7-day-old rats 35 , CNS suppression symptoms including hypothermia, hypoactivity and slow and/or irregular breathing, with some deaths, were observed in 43% (6/14) of the 533 mg/ kg (HED=57 mg/kg) dose group and 86% (12/14) of the 761 mg/kg (HED=81 mg/kg) dose group (Fig. 2) .
In a series of TK studies, 28 seven-day-old rats of both sexes were treated with a single dose of 761 mg/kg (HED=81 mg/kg). Symptoms such as hypothermia, paleness and hypoactivity were observed before death.
36
Symptoms such as dose-related increases in hypothermia, hypoactivity and slow/irregular breathing before death, and frequent findings of lung oedema at autopsy, suggest that the major cause of death is probably respiratory arrest due to central nervous system suppression. These are findings that were known from the Tx studies prior to approval. 
|
Roche to verify the causality showed that oseltamivir induced many symptoms which the manufacturer considered "item-related": alterations in respiration including decreased respiratory rate/gasping and altered mucous membrane/skin colour (paleness) prior to death.
52
Although the manufacturer denied causality 50 symptoms at 2 hours after administration that showed dose-related increases included lack of olfactory orientation (Fig. 3) , lack of cliff aversion and low or very low arousal (Fig. 4) . Among 58 pups in the 600 mg/ kg or higher groups that were alive at 2 hours without cliff aversion 24 (41%) were later found dead, dose-dependently (see footnote of Fig. 4) . 52 Among 17 animals that were alive with low or very low arousal in the 600 mg/kg or higher groups, 14 (82%) died thereafter within 24 hours. Among 51 animals that were alive without low arousal in the 600 mg/kg or higher groups, 14 (27%) died thereafter. Odd ratio for subsequent death with low arousal compared with no low arousal was 12.33 (95% CI: 3.07, 49.53, P<.0001). Among 60 animals in the control, 300 and 500 mg/kg group, none showed low arousal at 2 hours and none died within 24 hours.
These findings are consistent with clinically observed psychiatric symptoms in post-marketing spontaneous reports 6 (in particular, many cases in which sleep was followed by sudden death or abnormal behaviours with fatal outcome), some prospective cohort studies [16] [17] [18] [19] [20] and a systematic review of the cohort studies 21 and a systematic review of RCTs. tion. 60 Ethanol injection in the presence of oseltamivir also resulted in enhanced hypothermia. 59 Izumi et al. also reported that combination of oseltamivir with other neurostimulants altered synaptic plasticity and this may contribute to behavioural changes associated with the drug. 60 They discussed that the neuraminidase, the enzyme targeted by OC, can modulate synaptic function and possibly alter propagation of signals based on the fact that many ion channels are glycosylated. 59 Very low level of OC can affect the excitability of nociceptive neurons immediately after the administration of oseltamivir by reducing endogenous GM1 ganglioside. 61 QT prolongation is closely and immediately related to the plasma concentration of OC.
34,62
These findings suggest that if the concentration of OC in the brain increased and affected the excitability of the excitatory and/or inhibitory neurons and affected neuroplasticity, oseltamivir may contribute to behavioural changes, especially to the delayed-onset and prolonged type of psychiatric symptoms such as the case 8 in the case series. 6 However, the acute behavioural changes observed in the in vivo experiment by Izumi et al. 59 ,60 may be induced rather by OT considering all other findings.
| Respiratory suppression and respiratory arrest followed by cardiac arrest
Kimura et al. 63 reported that intravenous oseltamivir mg/kg expressed as free base) administered to mature rats caused F I G U R E 3 Oseltamivir dose and proportion of rats lacking olfactory orientation or died at 2 hours after dosing. Data from Refs. (50, 51) . For each dose group (including control), 20 rats were used. Proportion of rats lacking olfactory orientation or death 2 hours after dosing were 35%, 55%, 80%, 80%, 95%, 90% and 100% for control, 300, 500, 600, 700, 850, 1000 mg/kg group respectively. Odds of lacking olfactory orientation in 500 mg/kg group is higher than control group: OR=7. 43 
| Stimulatory or excitatory effects of oseltamivir on CNS
Suzuki et al. 64 reported that oseltamivir sialylates a serum glycolipid and that this modified glycolipid induced jump-down behaviour via stimulation of dopamine D2 receptors; they suggest that this mechanism may be involved in the abnormal behaviour seen in some children taking oseltamivir.
Hiasa et al., 65 through behavioural monitoring using automat- 
| Summary of this section
| SIMILARITY OF SPECTRUM OF REACTIONS IN HUMANS AND OTHER ANIMALS
Clinical adverse reactions reported following oseltamivir administration include sudden-onset type, delayed-onset type and others.
5,6,62
Similarities between sudden-onset type reactions in humans and those in other animals are summarized as follows.
Sudden-onset type reactions include nausea, vomiting, hypothermia and neuropsychiatric reactions such as abnormal behaviours, hallucination, psychotic symptoms and sudden respiratory arrest followed by cardiac arrest and death. These appear very shortly (from less than one hour up to 12 hours at most) after the first dose of oseltamivir and disappear rapidly unless respiratory arrest and sudden death or sequelae are induced. 5, 6 These reactions may disappear even if oseltamivir is continuously taken, although symptoms may reappear several times after subsequent intake. The underlying mechanism is discussed below in section 6.
| COHERENCE IN TOXICOKINETIC AND MOLECULAR LEVEL OF EVIDENCE
| Toxicokinetics: very high estimated concentrations in the brains of dead rats
The average maximum concentration (Cmax) in the brain after administration of 761 mg/kg of oral oseltamivir as free base was 144 μ mol/L for surviving 7-day-old rats, compared with only 2.3 μ mol/L for adult rats (all survived). 36 Ministry of Health, Labour and Welfare (Japan) ordered the pharmaceutical company to conduct toxicity and TK studies in order to reassess the causality of serious adverse effects on central nervous system of oseltamivir after the ministry contraindicated oseltamivir for children and adolescents aged 10-19 years.
Maximum concentration (Cmax) in the brain of surviving 7-day-old rats was estimated to be 64 times higher than that of mature (42-day-old) rats. 6, 36 This estimate was derived from the product of 6.4 times the difference in plasma Cmax (due to immaturity of CES1
)
and 10 times the difference in brain-to-plasma ratio due to immaturity of P-gp in the BBB.
30,31,33
However, this difference is underestimated, because it can be assumed that the average level of Cmax of juvenile rats that died may be higher than that of surviving rats. Hence, the ratio of brain Cmax of juvenile rats that died to that of mature rats may be higher. If the Cmax of oseltamivir in the brain of the died rat was two or three times higher than the average Cmax of survived rats, it could be 300, 400 μ mol/L or more. In fact, average Cmax of deceased juvenile rats in the 300-600 mg/kg group was estimated to be about 10 times higher than for surviving rats. Thus, concentrations could be 200 or more times greater in the brains of surviving 7-day-old rats than in the mature brains of adult rats, based on the data of post-marketing TK studies [50] [51] [52] (Table 2 ). Table 2 ), according to estimates using the data reported in the post-marketing toxicokinetic study. 
| Potential target receptors and enzymes for sudden-onset reactions
| For hypothermia and excitatory abnormal behaviours
Muraki et al. 58 showed that oseltamivir blocks nicotinic acetylcholine receptors (nAchRs: α 3 β 4 ) dose-dependently at concentrations of more than 3 μ mol/L: by 30%, 40%, 75% and 90% at concentrations of 3, 10, 30 and 100 μ mol/L, respectively. Concentrations of 0.3 and 1 μ mol/L had little effect. IC 50 is estimated to be between 10 and 30 μ mol/L. They also discussed the results by Lindeman et al. 66 stating "30 μ mol/L of oseltamivir inhibited Na + and Ca 2+ channel binding of their respective blockers by 38% and 41%, respectively, suggesting the possibility that oseltamivir blocks Na + and Ca 2+ channels."
58
As noted above, Hiasa et al. 65 found that oseltamivir, but not oseltamivir carboxylate, competitively and selectively inhibited human MAO-A. They estimated the Ki value to be 25-28 μ mol/L, and IC 50 was shown to be between 50 and 100 μ mol/L in their paper.
Hypothermia may be closely related to inhibition of nAch receptor, and abnormal behaviour of excitatory manner may be closely related to inhibition of MAO-A.
| For sensory, cognitive and respiratory impairment
However, a receptors, channels and/or enzymes related to impairment of sensory, cognition and respiratory suppression, respiratory arrest followed by cardiac arrest and death have not been known yet.
Among many agents acting on the central nervous system, those that induce all symptoms including hypothermia, excitatory abnormal behaviour, psychosis (both acute and chronic), sensory/cognitive/consciousness disturbance and respiratory arrest may be rare.
Central nervous system suppressants such as barbiturates, benzodiazepines and ketamine may induce disinhibition or dyscontrol leading to psychiatric reactions and respiratory arrest at higher dose. 54 It is rather difficult to explain delayed-onset and prolonged psychotic reactions only by GABAergic action. Ketamine, a non-competitive antagonist of NMDA/glutamate receptor and an agonist of certain subtype of GABA A , 54, 67 may better explain such delayed-onset psychotic reactions. 6, 7 Among the NMDA antagonists, ketamine is the most similar to the action/reaction of oseltamivir, because ketamine, but not phencyclidine, produces dose-dependent hypothermia 68 and respiratory depression leading to death in very high doses. 54 It induces acute schizophrenic symptoms, including hallucination, especially during recovery from anaesthesia. 54 Chronic low doses of ketamine also induce schizophreniform reactions in animals and humans.
69-72
Ketamine, but not phencyclidine (PCP), modulates α 6 β 2 δ and α 6 β 3 δ receptors. 50% effective concentrations (EC 50 ) for α 6 β 2 δ and α 6 β 3 δ T A B L E 2 Estimated plasma and brain concentrations (Cmax) of oseltamivir (as free base) for mature, surviving juvenile and deceased juvenile rats, and juvenile/mature ratio by survival state (calculated using the data from post-marketing TK test) subtype were 570 and 245 μ mol/L, although human anaesthetic concentration of ketamine is thought to be 1 μg/mL (3.6 μ mol/L), and that for respiratory arrest is thought to be 20 μ mol/L. Hence, far higher concentrations than 30 μ mol/L and various subtypes are necessary to determine EC 50 of ketamine to GABA A which is related to respiratory arrest by ketamine.
In determining inhibition (%) of GABA A receptor by oseltamivir, Among many receptors that Roche reported, several receptors were apparently inhibited dose-dependently by oseltamivir (Table 3) .
It should also be born in mind that EC 50 and/or IC 50 may differ greatly according to the substrate used.
Neuropsychiatric symptoms occurring in very early phases of treatment, such as acute behavioural change and respiratory depression leading to death, may be due to effects on the central nervous system (CNS) of unchanged oseltamivir phosphate (OP).
If oseltamivir has affinity to NMDA receptors, as suggested by the data reported in Lindeman et al., 66 and if oseltamivir is used for a long period of time, it could induce psychiatric reactions including psychosis, confusion and depression in humans, as reported in the RCTs for prophylaxis of influenza.
22,62
Gabapentin is an agent with anticonvulsant, antinociceptive and anxiolytic properties. It is a structural analogue of GABA or baclofen (a GABA B agonist), but it had been considered to have no direct or apparent effects on GABA A and GABA B receptors, although it has been reported to bind with nanomolar affinity to the auxiliary α 2 -δ subunit of voltage-dependent calcium channels (VD-CCs), 73 before the study by Ng et al. 74, 75 They reported that gabapentin is an agonist at the GABA B gb1a-gb2 heterodimer. 74 Selective gabapentin activation of GABA B receptors negatively coupled to VD-CCs may account for gabapentin actions.
75
On the other hand, VD-CCs, predominately the L-type channel, are proposed as a direct target of gabapentin, as it inhibits L-type calcium currents. 76 Baclofen, a GABA B agonist induces respiratory arrest (apnoea) in high dose in both animals 77 and humans. 78 Voltage-dependent calcium channels that were investigated by Lindeman et al. 66 are three L-type (DHP site, diltiazem site and verapamil site) and "N-type" Ca 2+ channels. Of these, L-type Ca 2+ channel (diltiazem site) was dose-dependently inhibited by unchanged oseltamivir (14% and 41% at 3 and 30 μ mol/L, respectively: Table 3 ). However, α 2 -δ subunit of VD-CC was not investigated by Lindeman et al.
66
It should also be considered that apnoea can be caused by apneusis that is induced by NMDA receptor blockade. Vomiting as an effect of neurological disturbance is consistent with the findings that vomiting in children increases only on day 1 of treatment but not thereafter 35 and that neuropsychiatric adverse reactions such as abnormal behaviour, delirium, unconsciousness [16] [17] [18] and respiratory arrest leading to death [5] [6] [7] 24 occur in the very early phase of oseltamivir treatment.
| Summary of this section
The maximum concentration (30 μ mol/L) in the study by the pharmaceutical company was insufficient for the binding assays compared with the brain levels of surviving juvenile rats (144 μ mol/L) and is far lower than that estimated in the dead rats (possibly 300 μ mol/L or more).
T A B L E 3 Activity of OP against molecular targets of high relevance for mood, cognition and behaviour in binding or functional assays Unchanged oseltamivir has various effects on the CNS that may be related to clinical findings including hypothermia, abnormal behaviours including with fatal outcome, and sudden death. Known and potential targets related to inhibitory and excitatory reactions to oseltamivir were discussed as in the following Summary and conclusions.
| SUMMARY AND CONCLUSIONS
Unchanged oseltamivir (OT) has CNS actions which are related to sudden-onset type reactions such as sudden death from respiratory arrest and abnormal behaviours with fatal outcome.
To date, it is known that unchanged oseltamivir inhibits nAchR and MAO-A, which are related to hypothermia and abnormal behaviours. Charles Bennett is a recipient of grants from the South Carolina
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